CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc., a vaccine discovery and development company, announced today that Jessica Baker Flechtner, Vice President of Research, will be presenting at the 5th Biennial Meeting of the Chlamydia Basic Research Society on Monday, March 21st, 2011 at the Crowne Plaza Redondo Beach & Marina Hotel in Redondo Beach, CA. Additional work will be presented in a poster session by Michele Picard, Senior Scientist at Genocea Biosciences.
About Genocea
Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell responses help confer protection. The company’s transformational discovery platform mines the natural immune response across diverse human populations in a way that radically reduces the risk, cost and time associated with antigen discovery. Genocea is currently developing vaccines for herpes simplex virus type-2 (therapeutic and prophylactic), a sexually transmitted disease affecting roughly 15 percent of the U.S. population; Chlamydia trachomatis, a sexually transmitted disease agent causing an estimated 90 million cases worldwide; Streptococcus pneumoniae, the leading killer of children under the age of 5 worldwide; and Plasmodium falciparum (malaria), of which there are more than 100 million cases globally. Visit www.genocea.com for more information.